硼替佐米诱导周围神经病的免疫调节治疗。
Immune modulation therapy in the management of bortezomib-induced peripheral neuropathy.
机构信息
Division of Hematology and Oncology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA.
出版信息
Exp Hematol Oncol. 2012 Aug 15;1(1):20. doi: 10.1186/2162-3619-1-20.
Abstract
Peripheral neuropathy (PN) is one of the most common side effects of bortezomib therapy. The majority of bortezomib-related PN is a sensory neuropathy of mild to moderate degree, and is reversible after dose reduction or discontinuation. However, occasionally bortezomib-induced neuropathy can be severe and affects motor and/or autonomic nerves, and may be mediated by immune process. The role of immune modulation therapy in the management of bortezomib-induced PN was not well established. Here, we reported a case of bortezomib-induced severe PN that responded well to plasma exchange and steroid treatment.
摘要
周围神经病变（PN）是硼替佐米治疗最常见的副作用之一。大多数硼替佐米相关的 PN 是轻度至中度感觉性神经病，在减少剂量或停药后可逆转。然而，硼替佐米诱导的神经病偶尔也可能很严重，影响运动和/或自主神经，并且可能由免疫过程介导。免疫调节治疗在硼替佐米诱导的 PN 中的作用尚未得到充分证实。在这里，我们报告了一例硼替佐米诱导的严重 PN，该病例对血浆置换和类固醇治疗反应良好。
相似文献
1
Immune modulation therapy in the management of bortezomib-induced peripheral neuropathy.硼替佐米诱导周围神经病的免疫调节治疗。
Exp Hematol Oncol. 2012 Aug 15;1(1):20. doi: 10.1186/2162-3619-1-20.
2
[Bortezomib-induced peripheral neuropathy in multiple myeloma patients].硼替佐米诱发多发性骨髓瘤患者的周围神经病变
Zhonghua Yi Xue Za Zhi. 2015 Oct;95(40):3297-301.
3
Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma.硼替佐米治疗晚期多发性骨髓瘤期间周围神经病变的特征及危险因素
Clin Lymphoma Myeloma. 2008 Jun;8(3):146-52. doi: 10.3816/CLM.2008.n.017.
4
The protective effects of lafutidine for bortezomib induced peripheral neuropathy.拉呋替丁对硼替佐米诱导的周围神经病变的保护作用。
J Blood Med. 2013 Jul 11;4:81-5. doi: 10.2147/JBM.S44127. Print 2013.
5
Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients.硼替佐米诱导的多发性骨髓瘤周围神经病：既往治疗与未治疗患者的比较。
Leuk Res. 2010 Apr;34(4):471-4. doi: 10.1016/j.leukres.2009.07.022. Epub 2009 Aug 11.
6
Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.硼替佐米治疗多发性骨髓瘤的神经毒性：单中心经验及文献综述
Cancer. 2007 Sep 1;110(5):1042-9. doi: 10.1002/cncr.22921.
7
Bortezomib and other proteosome inhibitors-induced peripheral neurotoxicity: From pathogenesis to treatment.硼替佐米和其他蛋白酶体抑制剂引起的周围神经毒性：从发病机制到治疗。
J Peripher Nerv Syst. 2019 Oct;24 Suppl 2:S52-S62. doi: 10.1111/jns.12338.
8
Immune-mediated neuropathies in myeloma patients treated with bortezomib.接受硼替佐米治疗的骨髓瘤患者的免疫介导性神经病
Clin Neurophysiol. 2008 Nov;119(11):2507-12. doi: 10.1016/j.clinph.2008.08.007. Epub 2008 Oct 1.
9
Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma.地塞米松联合给药方案对硼替佐米诱导的多发性骨髓瘤周围神经病变的影响
Br J Haematol. 2017 Sep;178(5):756-763. doi: 10.1111/bjh.14754. Epub 2017 Jun 7.
10
Assessment of bortezomib induced peripheral neuropathy in multiple myeloma by the reduced Total Neuropathy Score.通过降低总神经病变评分评估硼替佐米诱导的多发性骨髓瘤周围神经病变。
Leuk Lymphoma. 2014 Oct;55(10):2277-83. doi: 10.3109/10428194.2013.873535. Epub 2014 Mar 19.
引用本文的文献
1
Neuroinflammatory Process Involved in Different Preclinical Models of Chemotherapy-Induced Peripheral Neuropathy.涉及化疗诱导周围神经病变不同临床前模型的神经炎症过程。
Front Immunol. 2021 Feb 4;11:626687. doi: 10.3389/fimmu.2020.626687. eCollection 2020.
2
Non-Hematologic Toxicity of Bortezomib in Multiple Myeloma: The Neuromuscular and Cardiovascular Adverse Effects.硼替佐米对多发性骨髓瘤的非血液学毒性：神经肌肉和心血管不良反应
Cancers (Basel). 2020 Sep 7;12(9):2540. doi: 10.3390/cancers12092540.
3
Measuring symptoms as a critical component of drug development and evaluation in hematological diseases.测量症状作为血液系统疾病药物研发与评估的关键组成部分。
Clin Investig (Lond). 2013 Dec 1;3(12):1127-1138. doi: 10.4155/cli.13.108.
4
Bortezomib-induced painful peripheral neuropathy: an electrophysiological, behavioral, morphological and mechanistic study in the mouse.硼替佐米诱导的痛性周围神经病：在小鼠中的电生理学、行为学、形态学和机制研究。
PLoS One. 2013 Sep 12;8(9):e72995. doi: 10.1371/journal.pone.0072995. eCollection 2013.
本文引用的文献
1
Management of treatment-emergent peripheral neuropathy in multiple myeloma.多发性骨髓瘤治疗相关性周围神经病的管理。
Leukemia. 2012 Apr;26(4):595-608. doi: 10.1038/leu.2011.346. Epub 2011 Dec 23.
2
Inflammatory autoimmune neuropathy, presumably induced by bortezomib, in a patient suffering from multiple myeloma.由硼替佐米引起的炎症性自身免疫性神经病，发生于多发性骨髓瘤患者。
Int J Hematol. 2011 Jun;93(6):791-794. doi: 10.1007/s12185-011-0847-2. Epub 2011 May 7.
3
Bortezomib-induced inflammatory neuropathy.
J Peripher Nerv Syst. 2010 Dec;15(4):366-8. doi: 10.1111/j.1529-8027.2010.00287.x.
4
Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.单药硼替佐米用于既往未治疗的多发性骨髓瘤：疗效、周围神经病变特征以及与反应和神经病变的分子相关性
J Clin Oncol. 2009 Jul 20;27(21):3518-25. doi: 10.1200/JCO.2008.18.3087. Epub 2009 Jun 15.
5
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.在复发多发性骨髓瘤的III期APEX试验中硼替佐米对有症状的周围神经病变的可逆性：剂量调整指南的影响
Br J Haematol. 2009 Mar;144(6):895-903. doi: 10.1111/j.1365-2141.2008.07573.x. Epub 2009 Jan 16.
6
Immune-mediated neuropathies in myeloma patients treated with bortezomib.接受硼替佐米治疗的骨髓瘤患者的免疫介导性神经病
Clin Neurophysiol. 2008 Nov;119(11):2507-12. doi: 10.1016/j.clinph.2008.08.007. Epub 2008 Oct 1.
7
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.硼替佐米联合美法仑和泼尼松用于多发性骨髓瘤的初始治疗。
N Engl J Med. 2008 Aug 28;359(9):906-17. doi: 10.1056/NEJMoa0801479.
8
Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature.硼替佐米诱发的多发性骨髓瘤周围神经病变：文献综述
Blood. 2008 Sep 1;112(5):1593-9. doi: 10.1182/blood-2008-04-149385. Epub 2008 Jun 23.
9
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.硼替佐米治疗晚期多发性骨髓瘤期间周围神经病变的发生率、特征及可逆性
J Clin Oncol. 2006 Jul 1;24(19):3113-20. doi: 10.1200/JCO.2005.04.7779. Epub 2006 Jun 5.
10
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.硼替佐米或大剂量地塞米松用于复发的多发性骨髓瘤。
N Engl J Med. 2005 Jun 16;352(24):2487-98. doi: 10.1056/NEJMoa043445.
Zotero 插件